Prescribing information




ITP is associated with both increased platelet destruction and decreased platelet production.1–4

Increased platelet destruction:

  • Antiplatelet autoantibodies1–4
  • Autoreactive T cells1–3

Decreased platelet production:

  • Insufficient TPO1–3
  • Autoantibody or T cell-mediated megakaryocyte suppression1–3

Current immunosuppressive therapies used for ITP have non-specific actions to reduce the rate of platelet destruction.1 In doing so, these actions combat ITP by minimising the ‘increased platelet destruction’ pathway, however they also act with collateral damage by suppressing the normal function of the immune system.1–3


REVOLADE acts in the bone marrow by mimicking the actions of the natural hormone responsible for stimulating platelet production, known as thrombopoietin.2,3 This in turn increases platelet production. The increase in platelet production induced by REVOLADE helps to compensate for low platelet concentration, helping to reduce the risk of bruising and bleeding. Unlike immunosuppressive therapies, REVOLADE is specific for what it does and it will not interfere with the normal functioning of the immune system.1,5,6



REVOLADE, unlike larger TPO-RAs:

  • Complements endogenous TPO activity6,8
  • Does not promote neutralising antibodies6,8
  • Mimics endogenous TPO production with once-daily oral dosing7,8

Image showing the difference in the MOA of REVOLADE vs lager TPO agonists

Abbreviations: ITP, immune thrombocytopenia; TPO, thrombopoietin; TPO-RA, thrombopoietin-receptor agonist.


  1. McCrae K. Cleve Clin J Med. 2011;78(6):358–373.
  2. Lambert MP, Gernsheimer TB. Blood. 2017;129(21):2829–2835.
  3. Kashiwagi H, Tomiyama Y. Int J Hematol. 2013;98(1):24–33.
  4. Yazdanbakhsh K. Blood. 2016;128(6):750–751.
  5. REVOLADE Summary of Product Characteristics.
  6. Kuter DJ. Int J Hematol. 2013;98(1):10–23.
  7. Khellaf M, et al. Haematologica. 2013;98(6):881–887.
  8. Romiplostim Summary of Product Characteristics.
HCP19-C002b(1) June 2020.

For more information, refer to the REVOLADE® (eltrombopag olamine) Summary of Product Characteristics:

Legal Category: POM.

Aluminium blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/10/612/002 – 25 mg x 28 tablet pack £770, EU/1/10/612/005 – 50 mg x 28 tablet pack £1540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2310



Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]